eli lilly news - Search News

Eli Lilly to join lawsuit over GLP-1 shortage

Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has now ordered the Outsourcing Facilities Association to respond by January 15,

Hosted on MSN · 2d

Eli Lilly asks to join FDA in opposing lawsuit from pharmacies

CNBC's Becky Quick reports on news from Eli Lilly. US surgeon general urges cancer warnings for alcoholic drinks 14 Trader Joe's Items That Have Gained a Cult Following for a Good Reason

Becker's Hospital Review · 2d

Eli Lilly to join lawsuit over GLP-1 shortage: 4 things to know

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow compounding pharmacies to continue selling unapproved versions of the drugs, according to court documents obtained by Becker's .

The Hill · 3d

Pharma giant seeks to join lawsuit against FDA over weight loss drugs

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Pharmaceutical Technology31m

LY-4101174 by Eli Lilly and Co for Cervical Cancer: Likelihood of Approval

LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition ...

Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50

The board of Eli Lilly and Company ( NYSE:LLY ) has announced that it will be paying its dividend of $1.50 on the ...

2don MSN

Eli Lilly & Co. stock rises Friday, still underperforms market

Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...

Pharmaceutical Technology28m

Macupatide by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval

Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...

4don MSN

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

10d

Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Eli Lilly Unusual Options Activity

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

FiercePharma2d

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Is Eli Lilly Stock a Buy?

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Eli Lilly to join lawsuit over GLP-1 shortage

Related topics